Continuous Glucose Monitoring Market Size
Global Continuous Glucose Monitoring Market reached US$ 13.18 billion in 2025 and is expected to reach US$ 41.11 billion by 2033, growing with a CAGR of 14.8% during the forecast period 2026-2033.
Continuous Glucose Monitoring (CGM) devices are the advancement in diabetes management, where the blood glucose is under continuous monitor. The introduction of CGM devices integrated with insulin pumps using transmitters, receivers, and glucose sensors also increased their adoption due to improved convenience. The process of data collection through CGM has helped people keep track of their daily glucose levels.
Continuous Glucose Monitoring Market Scope
| Metrics | Details |
| Market CAGR | 14.8% |
| Segments Covered | By Component, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Regions Analyzed | North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world. |
| Major Companies Covered | FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, MiMedx Group, Inc, and among other major companies listed in the full report |
For more insights - Request Free Sample
Continuous Glucose Monitoring Market Dynamics
The global continuous glucose monitoring market growth is driven by the growing awareness about diabetes preventive care, new product launches, and supportive government initiatives. The development of novel and technologically advanced CGM is the prime focus of glucose monitoring device manufacturing companies. It offers a wide range of applications for all age-cohorts, healthcare settings.
Increasing adoption of continuous glucose monitoring (CGM) devices will drive the market growth
The patients reliant on insulin pumps or daily insulin injections, continuous glucose monitoring (CGM) establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia. As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) using continuous glucose monitoring have shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose. The trend follows in children, as well as those who use continuous glucose monitoring (CGM) on a regular basis. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia.
The current continuous glucose monitoring (CGM) models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid. Continuous glucose monitoring (CGM) devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time continuous glucose monitoring (CGM) devices can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose. However, lack of accuracy of continuous glucose monitoring (CGM) devices, need for frequent calibration, and inconsistency of medicare reimbursement are the major factors restraining the market growth.
Lack of adequate reimbursement for devices will hamper the market growth
However, lack of adequate reimbursement for devices is the key barrier to the adoption of the devices. This lack of coverage is likely due to the devices receiving FDA approval as adjunctive therapy to standard home blood glucose monitors. In case reimbursement is in a place like in the United States, only certain patient groups get the reimbursement that fulfills strict indications. This situation is somewhat surprising in view of the mounting evidence for benefits of CGM usage from clinical trials.
Continuous Glucose Monitoring Market Segmentation Analysis
The sensor segment is expected to grow at the fastest CAGR during the forecast period (2026-2033)
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated into the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period. Globally, diabetes mellitus has been of wide concern with its high global prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients.
Global Continuous Glucose Monitoring Market Geographical Share
North America region holds the largest market share of the global continuous glucose monitoring market
North America has the largest market share in the forecast period. Some of the factors that are driving the market growth in the North American region include increasing cases of diabetes and efforts taken by the national government to manage the disease at a larger level along with rising adoption of alternate and novel devices and the presence of key market players.
Continuous Glucose Monitoring Market Companies and Competitive Landscape
The continuous glucose monitoring market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics s.r.l, Echo Therapeutics, Inc., GlySens Incorporated, Johnson and Johnson, Medtronic Plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, Medtrum Technologies, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the continuous glucose monitoring market globally. For instance, in June 2020, Menarini Diagnostics has launched GlucoMen Day CGM, an innovative digital patch, wearable for fourteen days in a row, which monitors blood glucose and shows results directly on the smartphone.
Abbott Laboratories
Overview:
Abbott Laboratories is a U.S. health care company. The Company operates through four segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.
Product Portfolio:
FreeStyle Libre 2: FreeStyle Libre 2 is a sensor-based glucose monitoring system that comes with a reader and a sensor. The sensor is applied to the back of the upper arm and can be worn for up to 14 days.
Recent Developments
- March 2026 – Abbott expands Libre ecosystem with broader consumer and clinical integration
Abbott Laboratories is scaling its FreeStyle Libre platform across hospital, pharmacy, and over-the-counter channels, strengthening its position in both clinical and consumer metabolic monitoring markets. - March 2026 – Dexcom advances longer-duration and OTC CGM adoption
Dexcom Inc. is focusing on extended-wear sensors, real-time connectivity, and OTC CGM products (like Stelo) targeting non-insulin users and pre-diabetes populations. - February 2026 – Medtronic strengthens hybrid closed-loop insulin delivery integration
Medtronic plc is integrating CGM systems (Simplera Sync and Libre-based collaborations) with insulin pumps to enhance automated insulin delivery (AID) ecosystems. - February 2026 – Senseonics advances long-duration implantable CGM innovation
Senseonics Holdings Inc. is commercializing Eversense 365, a 1-year implantable CGM system, reducing sensor replacement frequency and improving long-term adherence. - January 2026 – Expansion of CGM into non-diabetic and wellness applications
CGM technology is increasingly used for metabolic health, fitness optimization, and pre-diabetes monitoring, expanding beyond traditional diabetes care.
